bevacizumab,gemcitabine,atezolizumab
roche
[]
imbrave151 phase 2 study of gem/cis/atezo/bev vs. gem/cis/atezo/placebo in advanced #biliarycancer improved pfs with bev hr 0.76, same orr ~24%, possible os benefit $gene
#gi23 
GI Medical Oncologist, Associate Professor of Medicine @Georgetown @RueschCenter @LombardiCancer, Ex-@SidwellFriends @Penn @KeckMedUSC keyboardist @BasementRiot